BioCentury | Oct 27, 2020
Distillery Therapeutics

ZDHHC7 and LYPLA2 identified as targets in Crohn’s, ulcerative colitis

...inhibitor extended survival.TARGET/MARKER/PATHWAY: Zinc finger DHHC-type containing 7 (ZDHHC7); lysophospholipase 2 (LYPLA2); Signal...
...Lin, Cornell University, Ithaca, N.Y.email: hl379@cornell.edu Claire Quang Cornell University Lysophospholipase 2 (LYPLA2) Autoimmune Inflammatory...
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Mar 5, 2019
Distillery Therapeutics

MC1R, ZDHHC13 and LYPLA2 as new targets for melanoma

...University School of Medicine, Boston, Mass. email: rutaocui@bu.edu Claire Quang Boston University School of Medicine Shandong University University of Oxford Lysophospholipase 2 (LYPLA2) Melanocortin...
BioCentury | Jan 5, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML); leukemia Neuroblastoma Ras viral oncogene (NRAS); lysophospholipase I (LYPLA1; APT-1) Cell culture studies suggest inhibiting APT-1 could help treat mutant NRAS-driven...
Items per page:
1 - 4 of 4